Search

Author/Creator Dodick, David W.

24. Efficacy, Tolerability, and Safety of DFN‐15 (Celecoxib Oral Solution, 25 mg/mL) in the Acute Treatment of Episodic Migraine: A Randomized, Double‐Blind, Placebo‐Controlled Study. Issue 1 (24th October 2019)

Authors:
Lipton, Richard B.; Munjal, Sagar; Brand‐Schieber, Elimor; Tepper, Stewart J.; Dodick, David W.
Journal:
Headache
Issue:
Volume 60:Issue 1(2020)
Page Start:
58
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

26. Evaluating the clinical utility of the patient‐identified most bothersome symptom measure from PROMISE‐2 for research in migraine prevention. Issue 6 (25th April 2022)

Authors:
Lipton, Richard B.; Goadsby, Peter J.; Dodick, David W.; McGinley, James S.; Houts, Carrie R.; Wirth, R. J.; Kymes, Steve; Ettrup, Anders; Østerberg, Ole; Cady, Roger; Ashina, Messoud; Buse, Dawn C.
Journal:
Headache
Issue:
Volume 62:Issue 6(2022)
Page Start:
690
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

27. Expert Consensus Recommendations for the Performance of Peripheral Nerve Blocks for Headaches – A Narrative Review. Issue 3 (13th February 2013)

Authors:
Blumenfeld, Andrew; Ashkenazi, Avi; Napchan, Uri; Bender, Steven D.; Klein, Brad C.; Berliner, Randall; Ailani, Jessica; Schim, Jack; Friedman, Deborah I.; Charleston, Larry; Young, William B.; Robertson, Carrie E.; Dodick, David W.; Silberstein, Stephen D.; Robbins, Matthew S.
Journal:
Headache
Issue:
Volume 53:Issue 3(2013)
Page Start:
437
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗